Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906223 | 0.95 | SMN1; SMN2 (0.40) | ALDH1A1DRD4GAASMN1; SMN2TSHR | |
| SCHEMBL19157365 | 0.80 | ADRB2 (0.39) | ALDH1A1GAASMN1; SMN2TSHRLMNA | |
| SCHEMBL9906222 | 0.76 | TSHR (0.50) | ALDH1A1GAATSHRLMNAKDM4E | |
| SCHEMBL4097981 | 0.76 | ALDH1A1 (0.41) | ALDH1A1GAASMN1; SMN2TSHRLMNA | |
| SCHEMBL6455028 | 0.72 | TSHR (0.47) | ALDH1A1SMN1; SMN2TSHREPHX1LMNA | |
| SCHEMBL10621456 | 0.72 | LMNA (0.50) | ALDH1A1SMN1; SMN2TSHREPHX1LMNA | |
| SCHEMBL28629837 | 0.71 | TSHR (0.58) | ALDH1A1GAATSHRLMNAKDM4E | |
| SCHEMBL16367382 | 0.70 | POLB (0.48) | ALDH1A1GAATSHRLMNAKCNJ1 | |
| SCHEMBL8543345 | 0.69 | TSHR (0.50) | ALDH1A1SMN1; SMN2TSHRLMNAKDM4E | |
| Alcohol SCHEMBL4094172 | 0.69 | EPHX1 (0.37) | DRD4SMN1; SMN2TSHREPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004642-B1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-07-26 | — | — | EP | disclosed |
| US-8518715-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2013-08-27 | — | — | US | disclosed |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2012-11-01 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| EP-2004642-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (Canada) Inc. (CA) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007104135-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (CANADA) INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | LPXN, FCGRT, POLQ | ALDH1A1 2764/4885DRD4 2891/4885GAA 49/4885 |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | LPXN, FCGRT, F13A1 | ALDH1A1 2824/4885DRD4 2913/4885GAA 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.